Project Grant R56HL173828
Award Date
9/24/24
Completion Date
8/31/25
Dollars Obligated
$408K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Tempe, AZ 85287, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $236,833 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Virginia Polytechnic Institute & State University (Virginia Tech) to develop a novel intracellular targeting nanobody that blocks Connexin 43 (Cx43)-mediated pathological proliferation of smooth muscle cells (SMCs). The project aims to design and test these small antibody fragments called nanobodies, which can enter cells, to disrupt the Cx43-Cyclin E...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
This Project Grant award, valued at $402,911.00, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant aims to develop a method for generating a large number of therapeutic nanovesicles (NVs) from mesenchymal stem cells (MSCs) using an extrusion process. These engineered "cell-drones" will be tested for their ability to promote tissue repair in mouse and porcine models of cardiac...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $698,017 to the University of California, San Diego to develop a nanotechnology-based cardiovascular vaccine. The primary goals are to create a vaccine targeting the S100A9 protein or S100A9 and PCSK9 to simultaneously reduce inflammation and cholesterol levels, thereby providing an atheroprotective effect against cardiovascular disease. The research will involve...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, is focused on developing a novel, EC-protective approach to mitigating intimal hyperplasia (IH) and restenosis following angioplasty procedures. The $2,158,878 award, granted on August 26, 2024, supports research by the University of Virginia to: 1) resolve the role of the ALDH1A3 protein in endothelial cell (EC) impairment associated with IH...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will provide $706,220 to the University of Illinois to conduct research on the role of nuclear pore components in vascular function. The key focus is investigating how phosphorylation of the nucleoporin NUP93 regulates the subcellular localization of the transcriptional regulator YAP, and the impact on endothelial inflammation and atherosclerosis. The research plan...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to uncover the prevalence and biological roles of protein arginylation, a critical post-translational modification, in cardiovascular development and disease. The $633,720 award, effective January 25, 2025 through November 30, 2028, aims to: 1) establish a chemical proteomics platform to comprehensively profile arginylation sites in cardiac cell and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is for the development of an endovascular prosthetic graft device that integrates nitric oxide (NO)-releasing polymer technology. The goal is to create a device that can reduce the incidence of infection, neointimal proliferation, and thrombosis - the three main clinical complications associated with current endovascular stent grafts. The total funding...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $717,246 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The Leland Stanford Junior University (Stanford University) to investigate the molecular mechanisms underlying cardiovascular toxicity induced by proteasome inhibitor cancer drugs. The project aims to leverage a mouse model, human induced pluripotent stem cells, and genomic analysis techniques to elucidate the role of aberrant alternative splicing in smooth...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $528,179 to the University of Miami to investigate reprogramming of bone marrow-derived monocytes as a novel strategy to improve neovascularization and outcomes in peripheral arterial disease and critical limb ischemia. The key objectives are to: 1) determine if extracellular vesicles mediate the systemic effect of ischemia training on monocyte reprogramming; 2)...